Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa

Experimental Neurology

Volumn 183, Issue 1, 2003, Pages 66-73

  Marin, C ^a,b   Bove J ^a   Bonastre, M ^a   Tolosa, E ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

6 Hydroxydopamine; Kappa opioid receptor; Levodopa; Motor fluctuations; Parkinson

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BENSERAZIDE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; LEVODOPA; OXIDOPAMINE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CHRONIC DRUG ADMINISTRATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; RAT;

EID: 0042190068     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00107-9     Document Type: Article

References (51)

1. Acri J.B., Thompson A.C., Shippenberg T. Modulation of pre-and postsynaptic dopamine D-2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse. 39:2001;343-350.
2. Arnt J., Scheel-Kruger K. GABAergic and glycinergic mechanisms with the substantia nigra pharmacological specificity of dopamine-independent contralateral turnung behavior and interactions with other neurotransmitters . Psychopharmacology. 62:1979;267-277.
3. Chavkin C., James I.F., Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 215:1982;413-415.
4. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244:1988;1067-1080.
5. Dykstra L.A., Gmerek D.E., Winger G., Woods J.H. Kappa opioids in rhesus monkeys. I. Diuresi, sedation, analgesia and discriminative stimulus effects. J. Pharmacol. Exp. Ther. 242:1987;413-420.
6. Engber T.M., Boldry R.C., Chase T.N. The k-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D-1 and D-2 agonists. Eur. J. Pharmacol. 20:1991;171-173.
7. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586-2588.
8. Gannon R.L., Terrian D.M. Kappa opioid agonists inhibit transmitter release from guinea pig hippocampal mossy fiber synaptosomes. Neurochem. Res. 17:1992;741-747.
9. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr., Sibley D.R. D-1 and D-2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
10. Gray A.M., Rawls S.M., Shippenberg T.S., McGinty J.F. The kappa opioid agonist, U69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J. Neurochem. 73:1999;1066-1074.
11. Giuffra, M., Mouradian, M.M., Davis, T.L., Ownby, J., Chase, T.N., 1993. Dynorphin agonist therapy of Parkinson's disease. Clin. Neuropharmacol. 16, 444-447.
12. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-Dopa, bromocriptine, or lisuride administration on proenkephalin-A and preproenkephalin-B mRNA levels in the striatum of 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155:1999;204-220.
13. Herrera-Marschitz M., Hökfelt T., Ungerstedt U., Terenius L. Functional studies with the opioid peptide dynorphin. acute effects of injections into the substantia nigra reticulata of naive rats. Life Sci. 33:1983;555-558.
14. Hill M.P., Brotchie J.M. Modulation of glutamate release by a k-opioid receptor agonist in rodent and primate striatum. Eur. J. Pharmacol. 281:1995;R1-R2.
15. Izenwasser S., Acri J.B., Kunko P.M., Shippenberg T. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D-2 receptors. Synapse. 30:1998;275-283.
16. Jackisch R., Hotz H., Herting G. No evidence for presynaptic opioid receptors on cholinergic, but presence of kappa receptors on dopaminergic neurons in the rabbit caudate nucleus involvement of endogenous opioids . Naunyn Schmiedebergs Arch. Pharmacol. 348:1993;234-241.
17. Jiménez A., Marin C., Bonastre M., Tolosa E. Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism. Brain Res. 839:1999;190-193.
18. Jolkkonen J., Jenner P., Marsden C.D. L-Dopa. reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol. Brain Res. 32:1995;297-307.
19. Kilpatrick N.C., Starr M.S. Involvement of dopamine in circling responses to muscimol depends on intranigral site of injection. Eur. J. Pharmacol. 69:1981;407-419.
20. Krebs M.O., Gauchy C., Desban M., Glowinski J., Kemel M.L. Role of dynorphin and GABA in the inhibitory regulation of NMDA. induced dopamine release in striosome and matrix-enriched areas of the rat striatum. J. Neurosci. 14:1994;2435-2443.
21. Lavin A., Garcia Muñoz M. Electrophysiological changes in susbtantia nigra after dynorphin administration. Brain Res. 369:1985;298-302.
22. Maisonneuve I.M., Archer S., Click S.D. U50, 488H, a K-opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 191:1994;57-60.
23. Maneuf Y.P., Mitchell I.J., Crossman A.R., Woodruff G.N., Brotchie J.M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683:1995;102-108.
24. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Autoradiographic differentiation of mu, delta and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7:1987;2445-2464.
25. Mansour A., Lewis M.E., Khachaturian H., Akil H., Watson S.J. Pharmacological and anatomical evidence of selective mu, delta and kappa opioid receptor binding in the rat brain. Brain Res. 399:1986;69-76.
26. Manzanares J., Lookingland K.J., Moore K.E. Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. J. Pharmacol. Exp. Ther. 256:1991;500-505.
27. Marin C., Engber T.M., Chaudhuri P., Peppe A., Chase T.N. Effects of kappa receptor agonists on D-1 and D-2 dopamine agonist and antagonist-induced behaviors. Psychopahrmacology. 213:1996;215-221.
28. Marin C., Jiménez A., Bonastre M., Chase T.N., Tolosa E. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats. Synapse. 36:2000;267-274.
29. Marin C., Jiménez A., Vila M., Bonastre M., Hirsch E.C., Agid Y., Tolosa E. LY293558, an AMPA glutamate receptor antagonist prevents and reverses levodopa-induced motor fluctuations in parkinsonian rats. Synapse. 42:2001;40-47.
30. Marin C., Papa S., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
31. Marsden C.D., Parkes J.D. Success and problems of longterm levodopa therapy in Parkinson's disease. Lancet. 1:1977;345-349.
32. Matsumoto R.R., Brinsfield K.H., Patrick R.L., Walker J.M. Rotational behavior mediated by dopaminergic and non-dopaminergic mechanisms after intranigral microinjections of specific mu, kappa and delta opioid agonists. J. Pharmacol. Exp. Ther. 246:1988;196-203.
33. Meshul C.K., McGinty J.F. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicle in axons. Neuroscience. 96:2000;91-99.
34. Morelli M., DiChiara G. Non-dopaminergic mechanisms in the turning behavior evoked by nigral opiates. Brain Res. 341:1985;350-359.
35. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bédard P.J., Di Paolo T. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D-2 agonist U91356A in continuous or intermittent mode of administration comparison with L-DOPA therapy. Mol. Brain Res. 49:1997;55-62.
36. Olianas M.C., Demontis G.M., Mulas G., Tagliamonte A. The striatal dopaminergic function is mediated by the inhibition of a nigral, nondopaminergic neuronal system via a striatonigral GABAergic pathway. Eur. J. Pharmacol. 49:1978;233-241.
37. Papa S.M., Engber T.M., Chase T.N. Motor fluctuations in levodopa-treated parkinsonian rats relation to lesion extent and treatment duration . Brain Res. 662:1994;69-74.
38. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1982;Academic Press, New York.
39. Rawls S.M., McGinty J.F. Kappa receptor activation attenuates I-trans-pyrrolidine-2,3-dicarboxylic acid-evoked glutamate levels in the striatum. J. Neurochem. 70:1998;626-634.
40. Rawls S.M., McGinty J.F., Terrian D.M. Presynaptic kappa opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes. J. Neurochem. 73:1999;1058-1065.
41. Robertson B.C., Hommer D.W., Skirboll L.R. Electrophysiological evidence for a non-opioid interaction between dynorphin and GABA in the susbtantia nigra of the rat. Neuroscience. 23:1987;483-490.
42. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Nat. Acad. Sci. USA. 89:1992;2046-2050.
43. Thompson L., Walker J.M. Inhibitory effects of the k-opiate U50,488 in the substantia nigra pars reticulata. Brain Res. 517:1990;81-87.
44. Tzaferis J.A., McGinty J.F. Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum. Mol. Brain Res. 93:2001;27-35.
45. VonVoigtlander P.F., Lahti R.A., Ludens J.H. U50,488 a selective and structurally novel non-mu (kappa) opioid agonist . Science. 218:1983;1136-1138.
46. Wang J.Q., Daunais J.F., McGinty J.F. Role of kainate/AMPA receptors in induction of striatal zif/268 and preprodynorphin mRNA by a single injection of amphetamine. Mol. Brain Res. 27:1994;118-126.
47. Wang J.Q., McGinty J.F. D-1 and D-2 receptor regulation preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methanphetamine. Synapse. 22:1996;114-122.
48. Wang J.Q., McGinty J.F. Intrastriatal injection of metabotropic glutamate receptor antagonist MCPG attenuates acute amphetamine-stimulated neuropeptide mRNA expression in rat striatum. Neurosci. Lett. 218:1996;13-16.
49. Werling L.L., Frattali A., Portoghese P.S., Takemori A.E., Cox B.M. Kappa receptor regulation of dopamine from striatum and cortex of rats and guinea pigs. J. Pharmacol. Exp. Ther. 246:1988;282-286.
50. Wood P.L., Kim H.S., Cosi C. Kappa receptor modulation of the nigrocollicular GABA pathway in the rat. Soc. Neurosci. Abstr. 113:1987;1445.
51. Zhang, F.Q., Li, J., Li, J-G., Ruggieri, M.R., Liu-Chen, L-Y., 2001. U50,488H-induced internalization and down-regulation of kappa opioid receptors. Molecular basis of differences between rat and human receptors. Soc. Neurosci. Abstr. 126.